Results 251 to 260 of about 187,044 (318)

Editorial: Diverse functions of drug transporters. [PDF]

Front Pharmacol
Granados JC, Cheung KWK, Prasad B.
europepmc   +1 more source

Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Axatilimab, a monoclonal antibody targeting colony‐stimulating factor 1 (CSF‐1) receptor, is approved in the US for the treatment of chronic graft‐versus‐host disease (cGVHD) after failure of ≥2 lines of systemic therapy. In this study, the effects of antidrug antibody (ADA) status on the pharmacokinetics, pharmacodynamics, efficacy, and safety of ...
Yan‐ou Yang, Xing Liu, Breann Barker, Xuecheng Zhang, Peter Ordentlich   +4 more
wiley   +1 more source

Simulation of pyrazinamide pharmacokinetics/pharmacodynamics in Vietnamese pulmonary tuberculosis patients

Thi Hoai Phan, S. Bui, Thi Le
openalex   +2 more sources

Quality by Design Approach for Preparation of Zolmitriptan/Chitosan Nanostructured Lipid Carrier Particles – Formulation and Pharmacodynamic Assessment

, 2020
Awadeen RH, Boughdady MF, Meshali MM
openalex   +1 more source

Improving Genotype Imputation in High‐Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Multiple imputation is well‐established for handling missing data, yet its use in high‐dimensional genetic datasets remains limited. Using pharmacokinetic tuberculosis simulations and SNP data (1000 Genomes Project), we compared machine learning (ML) and traditional approaches (e.g., mean imputation and complete‐case analysis) for imputation and ...
Innocent G. Asiimwe, Tao You, Daniel F. Carr, Munir Pirmohamed, Geraint Davies, Andrea L. Jorgensen, on behalf of the UNITE4TB Consortium   +6 more
wiley   +1 more source

Referee report. For: Virtual screening of zinc compounds similar to NSAIDS with better pharmacodynamic and pharmacokinetic profiles [version 1; peer review: 1 not approved]

Mohammed Hawash
openalex   +1 more source

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

Clinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin, Stein Schalkwijk, Isabelle J. Pouliquen, Alienor Berges, Nicholas Bird, Richard Follows, Daren Austin   +6 more
wiley   +1 more source

Exploring the Potential Impact of Creatine Supplementation on Anesthetic Outcomes: A Comprehensive Review. [PDF]

Cureus
Lehmeidi Y, Beck Neto T.
europepmc   +1 more source

Modeling Supports Combinatorial Effects Between Pharmacological and Non‐Pharmacological Interventions to Prevent Opioid‐Induced Cardiac Arrest

Clinical Pharmacology &Therapeutics, EarlyView.
Few studies have quantified the effects of non‐pharmacological interventions (e.g., rescue breathing) in the setting of community opioid overdose. We extended a previously validated model for opioid antagonists by incorporating the mechanism of rescue breathing, and quantified combinatorial effects between rescue breathing and various formulations of ...
Bradlee Thrasher, John Mann, Anik Chaturbedi, Shilpa Chakravartula, Hamed Meshkin, Affan Affan, Alexander Galluppi, Ji Young Kim, Nigar Karimli, Yue Han, Zachary Dezman, Jeffry Florian, Zhihua Li   +12 more
wiley   +1 more source

Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium. [PDF]

J Antimicrob Chemother
Hayashi Y, Takahashi M, Sasaki M, Suzuki K, Mizukami Y, Liu X, Enoki Y, Taguchi K, Yamaguchi T, Tateda K, Matsumoto K.   +10 more
europepmc   +1 more source